Finance

Lists
Q1 2027 earnings • released • EPS miss -5.55% • Revenue beat +4.07%
See results
TORNTPHARM:NSE
Torrent Pharmaceuticals Ltd
₹5,020.00
-2.01%
(-102.80) 1D
Aug 3, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for TORNTPHARM...
Open
₹5,250.00
High
₹5,250.00
Low
₹5,007.50
Mkt. cap
1.70T
Avg. vol.
769.54K
Volume
841.75K
Dividend
0.76%
Quarterly dividend
₹9.50
Ex-dividend date
May 29, 2026
P/E ratio
80.19
52-wk high
₹5,250.00
52-wk low
₹3,480.60
EPS
₹62.60
Shares outstanding
170.00M
No. of employees
18K
Open
₹5,250.00
High
₹5,250.00
Low
₹5,007.50
Mkt. cap
1.70T
Avg. vol.
769.54K
Volume
841.75K
Dividend
0.76%
Quarterly dividend
₹9.50
Ex-dividend date
May 29, 2026
P/E ratio
80.19
52-wk high
₹5,250.00
52-wk low
₹3,480.60
EPS
₹62.60
Shares outstanding
170.00M
No. of employees
18K
News stories
From sources across the web
Profile
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics. Wikipedia
About Torrent Pharmaceuticals Ltd
CEO-
Employees18.3K
Founded1959
HeadquartersAhmedabad, Gujarat, India
SectorPharmaceutical industry
Websitetorrentpharma.com
Last report
Jul 30, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹15.30 / ₹16.20
-5.55%miss
Revenue / Est. (INR)
49.21B / 47.29B
+4.07%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
33.02B
33.03B
41.97B
49.21B
Cost of goods sold
8.00B
7.99B
10.15B
11.63B
Cost of revenue
8.00B
7.99B
10.15B
11.63B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.27B
6.51B
8.48B
8.93B
Operating expense
16.23B
16.22B
23.34B
26.87B
Total operating expenses
24.23B
24.21B
33.49B
38.50B
Operating income
8.79B
8.82B
8.48B
10.71B
Other non operating income
-270.00M
-130.00M
794.40M
-120.00M
EBT including unusual items
7.91B
8.14B
5.29B
7.33B
EBT excluding unusual items
8.04B
8.24B
5.46B
7.54B
Income tax expense
2.00B
1.79B
1.65B
1.67B
Effective tax rate
25.28%
21.99%
31.18%
22.78%
Other operating expenses
7.92B
7.65B
9.78B
12.01B
Net income
5.91B
6.35B
3.89B
5.66B
Net profit margin
17.90%
19.22%
9.28%
11.50%
Earnings per share
17.75
19.00
12.85
15.30
Interest and investment income
-
-
384.30M
-
Interest expense
-480.00M
-450.00M
-2.36B
-3.05B
Net interest expenses
-480.00M
-450.00M
-1.97B
-3.05B
Depreciation and amortization charges
2.04B
2.06B
5.08B
5.93B
EBITDA
10.82B
10.69B
11.12B
13.35B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps